BCL2 and cancer: Another prominent effect of the azacitidine treatment was the significant suppression of BCL2, both at the mRNA and protein levels, which has previously been reported as a key mechanism underlying azacitidine-mediated cytotoxicity in various cancer cell lines (namely P39, HL60, and Jurkat) [41].